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reality in the clinic. Taking allogeneic, 
hematopoietic donor cells will result in 
therapy-related mortality and morbidity 
that might push the risk – benefit ratio 
in the wrong direction. And last but 
not least, gene therapy approaches have 
their own set of issues — for example, 
vector safety, which becomes especially 
apparent when stem cells have to be 
transduced. 
 Th is is what most of us will love about 
the science part: seeing how the puzzle 
will be solved. In the meantime, we should 
think hard about how to help our patients. 
Ensuring safety and guided by an acceptable 
risk – benefit ratio, cellular therapies will 
have to be developed at the bench and the 
bedside, and the paper by Yeagy  et al. 1 is a 
great example of a very involved experimen-
tal system adding pieces to the puzzle to 
make a diff erence. 
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 Hexokinases (HKs) catalyze the fi rst com-
mitted step of glucose (Glc) metabolism, 
namely, the phosphorylation of Glc to 
yield glucose-6-phosphate. Th is reaction 
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maintains the concentration gradient per-
mitting facilitated Glc entry into cells and 
also initiates all major pathways of Glc 
utilization. 1 As such, this rate-controlling 
step is ideally positioned to infl uence the 
magnitude and direction of Glc flux 
within cells. Th e major HKI and HKII iso-
forms also exhibit a novel capacity for 
specific physical and functional inter-
action with mitochondria that directly 
couples and coordinates oxidative 
 phosphorylation with cytosolic Glc fl ux. 1,2 
Mitochondrial HKs have recently emerged 
as major mediators of the antiapoptotic 
eff ects of growth factors. 1,3,4 Competition 
with apoptogenic Bax and Bak for com-
mon mitochondrial binding sites and 
direct metabolic coupling with oxidative 
phosphorylation have both been impli-
cated in these effects. When examined 
in cells with intact mitochondria, partial 
or complete Glc dependence has been 
observed, suggesting specifi c metabolic 
requirements. 1 Gall  et al. 5 (this issue) now 
report the ability of mitochondrial HK to 
mitigate Bax-induced apoptosis in an 
adenosine triphosphate (ATP) depletion 
model of proximal tubule cell injury, sug-
gesting that metabolism  per se is not an 
absolute prerequisite for Bax antagonism. 
 Under normal conditions, proximal 
tubules exhibit a lower relative glycolytic 
capacity than other nephron segments 
and a heavy reliance on non-Glc energy 
substrates. 6 Although it does not follow 
that proximal tubule cells do not — or 
cannot — utilize Glc, these observations 
have led to the common misperception 
that Glc metabolism is unimportant in 
this nephron segment. Th ere is, however, 
con siderable evidence to the contrary. All 
mammalian cells can utilize Glc, 2 includ-
ing proximal tubule cells. 6 – 9 Although less 
than that observed in distal nephron seg-
ments, the total Glc-phosphorylating 
capacity of freshly isolated proximal 
tubules 10,11 is not much lower than that 
reported for normal muscle or adipose —
 tissues largely responsible for systemic Glc 
disposal. Th is suggests a substantial cellu-
lar capacity for Glc utilization, with the 
caveat that only a fraction of this capa-
city is probably required to support the 
demands of even the most Glc-avid cell 
types. 2 Th e corresponding ability to oxi-
dize Glc 11 is similarly comparable to that 
observed in adipocytes. As the only energy 
substrate that can be eff ectively utilized in 
the absence of O 2 , Glc has particular rele-
vance to ischemic or hypoxic conditions, 1 
so it is of considerable interest that proxi-
mal tubule glycolytic activity increases 
 in vivo following brief ischemia. 7 Similar 
changes can prevent ATP depletion, cellu-
lar injury, and transport dysfunction in 
proximal tubule preparations subjected 
to brief hypoxia or chemical anoxia. 12 
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These changes have obvious adaptive 
implications and could contribute to the 
observed resistance of renal epithelial cells 
to hypoxia – reoxygenation injury when 
cultured in the presence of Glc. 13 It has 
also been suggested that HK may specifi -
cally contribute to the known salutary 
eff ects of growth factors in the kidney via 
Glc-dependent mechanisms. 9 
 Adenine nucleotide cycling between 
HK and oxidative phosphorylation 
 ( Figure 1 ) supports state 3 respiration and 
is associated with mitochondrial integrity, 
reduced reactive oxygen species genera-
tion, and cell survival. 1 Respiratory-chain 
inhibition in ATP depletion models dis-
rupts this cycling and, in combination 
with glycolytic substrate withdrawal and /
 or antagonism, results in global collapse 
of both oxidative and non-oxidative cellu-
lar energy metabolism. Glc-dependent 
phosphatidylinositol-3  -kinase – Akt 
antagonism of Bax- or Bak-mediated 
apoptosis is well described in cells with 
functioning mitochondria and was the 
original basis for examining the potential 
contributions of HK. 1,3 Similar protection 
in an ATP depletion model is thus some-
what surprising, but it supports the notion 
that HK physically antagonizes apop-
togenic Bax interaction with  mitochondria 
( Figure 1 ), presumably via steric or con-
formational means. It does not, however, 
exclude complementary metabolic contri-
butions that may simply be masked in 
these models. In fact, stringent require-
ments for the removal of Glc and / or the 
antagonism of its metabolism in tradi-
tional ATP depletion models of proxi-
mal tubular injury could be viewed as a 
tacit acknowledgment of the general 
 importance of Glc metabolism to survival 
in these cells. Nonetheless, the contention 
that metabolism is not obligatory for 
mitochondrial HK antagonism of Bax-
mediated apoptosis is supported by 
demon strations that HKI and HKII 
mutants defi cient in either catalytic acti-
vity or mitochondrial binding capacity 
retain partial antiapoptotic eff ectiveness, 
with both functions required for full 
eff ect. 4 Voltage-dependent anion channels 
(VDACs) are an integral component of 
the putative metabolic exchange conduit 
coupling HK to oxidative phosphoryla-
tion, 1 so the ability of mitochondrial HK 
to antagonize apoptosis in VDAC-defi -
cient cells 14 may also support this view. 
Although these fi ndings neither establish 
nor exclude metabolic roles for HK in 
antagonizing apoptosis, they are compat-
ible with the premise that catalytic capa-
city alone is probably not the only  raison 
d ’ ê tre for multiple HK isoforms. 2 Addi-
tional lines of evidence suggest that 
 physical competition with Bax for mito-
chondrial interaction is not the only 
mechanism whereby HK contributes to 
cell survival. 1,4 For example, mitochon-
drial HK prevents apoptosis in cells 
lacking both Bax and Bak, and direct adeno-
sine diphosphate recycling by bound 
HK reduces mitochondrial reactive oxy-
gen species generation. 1 HK-gated fl ux 
through the pentose phosphate path-
way also has well-described antiapoptotic 
roles involving both organic and inorganic 
peroxide detoxifi cation and redox- coupled 
caspase inactivation. 1 Such mechanisms 
may contribute to the partial protec-
tion observed in cells overexpressing 
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 Figure 1  |  Antiapoptotic and metabolic roles for mitochondrial hexokinase. ( a ) Hexokinase (HK) directly antagonizes apoptogenic Bax interaction 
with mitochondrial contact sites, which represent a major point of convergence for these competing survival and apoptotic signals. Glycogen synthase 
kinase 3  plays dual roles in apoptosis: an active role in Bax activation and a permissive role in promoting the dissociation of competing mitochondrial 
HK. ( b ) Mitochondrial HK maintains the  ‘ open ’ configuration of voltage-dependent anion channels (VDACs), allowing anionic metabolite entry and 
exit from mitochondria and directly coupling oxidative phosphorylation with cytosolic metabolism through local adenine nucleotide recycling. 
See references  1 and  5 for additional details and citations. ADP, adenosine diphosphate; AIF, apoptosis-inducing factor; ANT, adenine nucleotide 
translocator ; ATP, adenosine triphosphate; Glc, glucose; Glc-6-P, glucose-6-phosphate; GSK3  , glycogen synthase kinase 3  . 
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cata lytically active HK mutants that lack 
mitochondria-binding capacity. 4 
 Th e distribution, regulation, and func-
tion of individual HK isoforms have been 
incompletely delineated in the kidney. An 
important by-product of the study by Gall 
 et al. involves anatomic localization of 
endogenous HKII expression to the proxi-
mal tubule. 5 Expression of this inducible 
isoform is consistent with a putative role 
in determining apoptotic susceptibility 
within this segment and also has impor-
tant regulatory implications. 1 It bears not-
ing, however, that ubiquitous HKI is the 
predominant renal isoform and is capable 
of functional substitution for HKII in 
protecting cells against apoptogenic 
stress. 1,4,5,9 As such, endogenous coex-
pression of HKI in proximal tubule cells 5 
suggests potential for redundancy that 
needs to be more fully characterized to 
yield a better understanding of the relative 
contributions of individual isoforms. 
 Reduced HKII abundance in stressed 
cells 5 is unexpected from a teleological 
perspective and would be predicted to be 
maladaptive. Hypoxia has known direc-
tionally opposite eff ects on glycolysis and 
the expression of glycolytic enzymes, 
including HKII, in viable cells. 1,7,12 
 Ubiquitin-dependent proteolysis is a 
 plausible, but untested, explanation for 
these discrepant observations, 5 although 
the relevance of this pathway to HK turn-
over has been questioned in the absence 
of oxidative modifi cation. 2 Notably, sub-
strate binding conformationally reduces 
both HK proteolytic susceptibility and 
thermal lability  in vitro , 2 but the relevance 
of these observations to HK abundance in 
intact cells deprived of Glc is unknown. 
Whether short-term decreases are later 
counterbalanced by adaptive increases in 
endogenous HK expression also remains 
to be established. Knowledge of the corres-
ponding changes in HKI abundance and 
compartmentalization — and a better 
understanding of individual isoform con-
tributions to the total — are also needed to 
meaningfully interpret these changes. 
 Mitochondrial HK binding is inherently 
complex, and its fundamental determinants 
are still incompletely understood. Major 
control is exerted by biologically relevant 
concentrations of the HK reaction product 
glucose-6-phosphate, 1,2 and two major cate-
gories of HK binding sites have been 
described based on the ability (Type A) or 
inability (Type B) of glucose-6-phosphate 
to dissociate mitochondrial HK. 2,15 As 
such, all mitochondrial binding sites may 
not be functionally equivalent or regulated 
in the same manner. Relatively small 
changes in HK expression and compart-
mentalization have been associated with 
profound functional consequences, 3,9 so it 
is reasonable to speculate that physically 
and functionally distinct subsets of bound 
HK may account for the observed changes. 
Th e molecular basis for discrete binding 
sites is unknown, but Type A and Type B 
sites appear to reside on the same mito-
chondria and bind both HKI and HKII. 2 A 
better understanding of the complexity and 
heterogeneity of HK binding sites is clearly 
needed to advance the fi eld. 
 Th e extent to which ATP deple tion mod-
els mimic  in vivo ischemia is  debatable, and 
requirements for ATP as a cofactor for apop-
tosome formation may limit their utility in 
the study of  antiapoptotic  mechanisms. 
Th ese considerations aside, ATP depletion 
may provide a useful platform for charac-
terizing metabolism- independent HK con-
tributions to Bax and Bak antagonism, but 
other models are needed to address meta-
bolic dependencies. 
 Although numerous questions remain, 
Gall  et al. 5 have addressed issues of fun-
damental importance to all cells, includ-
ing renal epithelial cells — namely, the 
mechanisms whereby cells respond to 
metabolic stress and the molecular deter-
minants of apoptotic susceptibility. Th e 
demonstration that HK can antagonize 
apoptosis downstream of both glycogen 
synthase kinase 3  (GSK3  ) and Bax acti-
vation despite global metabolic disruption 
indicates that metabolism  per se is not 
obligatory for this eff ect and may suggest 
novel targets for therapeutic modulation 
of apoptotic susceptibility. Hopefully, 
these studies will prompt a reexamination 
of both HK and Glc metabolism in the 
kidney, as these lines of inquiry have the 
potential to challenge or extend present 
dogma regarding the fundamental deter-
minants of renal epithelial cell survival, as 
well as the specifi c physiologic and patho-
physiologic roles played by Glc meta-
bolism and HK in the proximal tubule and 
elsewhere within the kidney. 
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